ACH-3102: Phase II started

Achillion began an open-label, partial-crossover Phase II trial to evaluate 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir once daily for 8 weeks in 12 treatment-naïve patients with HCV genotype 1 infection. Achillion said that the protocol allows for the enrollment of additional patients with HCV infection to receive the combination once daily for 6 weeks. The company expects preliminary data from the 8-week cohort in the summer. ...